Deep Vein Thrombosis (DVT) - Pipeline Review, H2 2014

Published: Aug, 2014 | Pages: 84 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Deep Vein Thrombosis (DVT) - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Deep Vein Thrombosis (DVT) - Pipeline Review, H2 2014', provides an overview of the Deep Vein Thrombosis (DVT)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Deep Vein Thrombosis (DVT), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Deep Vein Thrombosis (DVT) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Deep Vein Thrombosis (DVT)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Deep Vein Thrombosis (DVT) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Deep Vein Thrombosis (DVT) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Deep Vein Thrombosis (DVT) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Deep Vein Thrombosis (DVT)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Deep Vein Thrombosis (DVT) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Deep Vein Thrombosis (DVT) Overview 7
Therapeutics Development 8
Pipeline Products for Deep Vein Thrombosis (DVT) - Overview 8
Pipeline Products for Deep Vein Thrombosis (DVT) - Comparative Analysis 9
Deep Vein Thrombosis (DVT) - Therapeutics under Development by Companies 10
Deep Vein Thrombosis (DVT) - Therapeutics under Investigation by Universities/Institutes 12
Deep Vein Thrombosis (DVT) - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Deep Vein Thrombosis (DVT) - Products under Development by Companies 16
Deep Vein Thrombosis (DVT) - Products under Investigation by Universities/Institutes 17
Deep Vein Thrombosis (DVT) - Companies Involved in Therapeutics Development 18
Bristol-Myers Squibb Company 18
F. Hoffmann-La Roche Ltd. 19
Generex Biotechnology Corporation 20
Bayer AG 21
Merrion Pharmaceuticals Plc 22
Regado Biosciences, Inc. 23
Thrombotargets Corporation 24
Diakron Pharmaceuticals, Inc. 25
Armetheon, Inc. 26
Deep Vein Thrombosis (DVT) - Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Target 28
Assessment by Mechanism of Action 30
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
apixaban - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
rivaroxaban - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
tecarfarin - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
TRX-1 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
DP-4088 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
REG-2 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Low Molecular Weight Heparin - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
TT-105 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
fondaparinux sodium - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
RNAi Oligonucleotide for DVT - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Small Molecules for Hematological Disorders and Cancer - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Deep Vein Thrombosis (DVT) - Recent Pipeline Updates 54
Deep Vein Thrombosis (DVT) - Dormant Projects 69
Deep Vein Thrombosis (DVT) - Discontinued Products 70
Deep Vein Thrombosis (DVT) - Product Development Milestones 71
Featured News & Press Releases 71
Jul 29, 2014: European Commission Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE 71
Jul 15, 2014: Pradaxa (dabigatran etexilate) Now Available in the UK for the Treatment of Deep Vein Thrombosis and Pulmonary Embolism and Prevention of Recurrence 73
Jun 27, 2014: Eliquis (apixaban) Receives CHMP Positive Opinion for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE 73
Jun 26, 2014: Boehringer Ingelheim's Investigational Antidote for Pradaxa (dabigatran etexilate mesylate) Receives FDA Breakthrough Therapy Designation 74
May 28, 2014: Boehringer Ingelheim Announces Comprehensive Settlement of U.S. Pradaxa (dabigatran etexilate mesylate) Litigation 75
May 22, 2014: Antidote for rapid reversal of Pradaxa progresses into next stage of clinical investigation with study in patients 76
May 15, 2014: As the benefits and safety of Pradaxa are once again confirmed, Boehringer Ingelheim continues to look for new ways for Pradaxa to help more patients 76
Apr 25, 2014: Positive CHMP opinion for Pradaxa in treatment of deep vein thrombosis and pulmonary embolism and prevention of repeat blood clots 78
Mar 14, 2014: U.S. FDA Approves Eliquis (apixaban) To Reduce The Risk Of Blood Clots Following Hip Or Knee Replacement Surgery 80
Feb 24, 2014: Thrombogenics' Board Announces Decision to Explore Strategic Options for the Company 81
Appendix 83
Methodology 83
Coverage 83
Secondary Research 83
Primary Research 83
Expert Panel Validation 83
Contact Us 84
Disclaimer 84

List of Tables
Number of Products under Development for Deep Vein Thrombosis (DVT), H2 2014 8
Number of Products under Development for Deep Vein Thrombosis (DVT) - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 11
Number of Products under Investigation by Universities/Institutes, H2 2014 12
Comparative Analysis by Late Stage Development, H2 2014 13
Comparative Analysis by Clinical Stage Development, H2 2014 14
Comparative Analysis by Early Stage Development, H2 2014 15
Products under Development by Companies, H2 2014 16
Products under Investigation by Universities/Institutes, H2 2014 17
Deep Vein Thrombosis (DVT) - Pipeline by Bristol-Myers Squibb Company, H2 2014 18
Deep Vein Thrombosis (DVT) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 19
Deep Vein Thrombosis (DVT) - Pipeline by Generex Biotechnology Corporation, H2 2014 20
Deep Vein Thrombosis (DVT) - Pipeline by Bayer AG, H2 2014 21
Deep Vein Thrombosis (DVT) - Pipeline by Merrion Pharmaceuticals Plc, H2 2014 22
Deep Vein Thrombosis (DVT) - Pipeline by Regado Biosciences, Inc., H2 2014 23
Deep Vein Thrombosis (DVT) - Pipeline by Thrombotargets Corporation, H2 2014 24
Deep Vein Thrombosis (DVT) - Pipeline by Diakron Pharmaceuticals, Inc., H2 2014 25
Deep Vein Thrombosis (DVT) - Pipeline by Armetheon, Inc., H2 2014 26
Assessment by Monotherapy Products, H2 2014 27
Number of Products by Stage and Target, H2 2014 29
Number of Products by Stage and Mechanism of Action, H2 2014 31
Number of Products by Stage and Route of Administration, H2 2014 33
Number of Products by Stage and Molecule Type, H2 2014 35
Deep Vein Thrombosis (DVT) Therapeutics - Recent Pipeline Updates, H2 2014 54
Deep Vein Thrombosis (DVT) - Dormant Projects, H2 2014 69
Deep Vein Thrombosis (DVT) - Discontinued Products, H2 2014 70